Optimisation of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses

Influenza and other Respiratory Viruses

Volumn 9, Issue 6, 2015, Pages 331-340

  Lin, Yipu ^a   Gu, Yan ^a   Wharton, Stephen A ^a   Whittaker, Lynne ^a   Gregory, Victoria ^a   Li, Xiaoyan ^a,b   Metin, Simon ^a,c   Cattle, Nicholas ^a   Daniels, Rodney S ^a   Hay, Alan J ^a   Mccauley, John W ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b Tianjin Centers for Disease Control and Prevention   (China)

^c KING'S COLLEGE   (United Kingdom)

Author keywords

Antigenicity; Haemagglutination inhibition; Influenza; Micro neutralisation

Indexed keywords

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGENICITY; ARTICLE; CELL LINE; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION TEST; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA VIRUS; INTERMETHOD COMPARISON; MICRO NEUTRALIZATION ASSAY; MINIPIG; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; VIRAL PLAQUE ASSAY; VIROGENESIS; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS TITRATION;

EID: 84944051279     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12333     Document Type: Article

References (21)

1. Ampofo WK, Al Busaidy S, Cox NJ et al. Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conferences (CICG) Geneva, Switzerland, 7 to 9 December 2011. Vaccine 2013; 31:3209-3221.
2. Medeiros R, Escriou N, Naffakh N, Manuguerra JC, van der Werf S. Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology 2001; 289:74-85.
3. Nobusawa E, Ishihara H, Morishita T, Sato K, Nakajima K. Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology 2000; 278:587-596.
4. Lin YP, Xiong X, Wharton SA et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A 2012; 109:21474-21479.
5. Lin YP, Gregory V, Collins P et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol 2010; 84:6769-6781.
6. Saito T, Nakaya Y, Suzuki T et al. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J Med Virol 2004; 74:336-343.
7. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706-709.
8. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166-174.
9. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-943.
10. Sullivan K, Kloess J, Qian C et al. High throughput virus plaque quantitation using a flatbed scanner. J Virol Methods 2012; 179:81-89.
11. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77:8418-8425.
12. WHO Global Influenza Surveillance Network.Manual for the laboratory diagnosis and virological surveillance of influenza. http://www.who.int/influenza/gisrs_laboratory/en/2011.
13. Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 2008; 46:2189-2194.
14. Robertson JS. Clinical Influenza viruses and the embryonated hen's egg. Rev. Med. Virol. 1993; 3:97-106.
15. WHO. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Wkly Epidemiol Rec 2014; 89:93-104.
16. Walker DL, Horsfall FL Jr. Lack of identity in neutralizing and hemagglutination-inhibiting antibodies against influenza viruses. J Exp Med 1950; 91:65-86.
17. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373-378.
18. Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-251.
19. Corti D, Voss J, Gamblin SJ et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-856.
20. Gambaryan AS, Robertson JS, Matrosovich MN. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology 1999; 258:232-239.
21. Jackson DC, Brown LE, White DO. Antigenic determinants of influenza virus haemagglutinin. VI. Antigenic characterization of the oligosaccharide sidechains form HA1 of influenza virus haemagglutinins. J Gen Virol 1981; 52:163-168.